Download Document

Jorge Duconge PhD, MSc, BSc Pharm
Affiliation:
University of Puerto Rico
Pharmaceutical Sciences
"Cardiovascular and Related Diseases"
Title: Professor
Rank: Professor
Address:
UPR-Medical Sciences Campus School of Pharmacy PO Box 365067
Pharmacy Bldg., 3rd floor, Rm 325-14
San Juan, PR 00936-5067
Contact:
Email: [email protected]
Telephone: (787) 758-2525 ext. 5312
Narrative
Dr. Jorge Duconge is a Professor of Pharmacokinetics and Pharmacogenomics in the Department of
Pharmaceutical Sciences at the School of Pharmacy, University of Puerto Rico Medical Sciences
Campus.
Dr. Duconge obtained a Baccalaureate in Pharmacy, BSc Pharm (1995, Gold Medal Honors List);
Master’s degree in Experimental Pharmacology (1997); and a PhD degree (1999) from the School of
Pharmacy, University of Havana. He also completed an advanced Residential Program in
pharmacokinetics at Cambridge University, UK in 1998; population pharmacokinetics at State
University of New York at Buffalo in 2006, and pharmacometrics (University of Auckland in New
Zealand, 2003). He has also spent a mini-sabbatical at Hartford Hospital and the Genomas
Laboratory of Personalized Health, CT in 2007, receiving hands-on training on DNA-typing. In
addition, he completed the Genetic Analysis for Admixture and Epidemiology Studies in Latin
American Populations (University of California at San Francisco (UCSF), USA) in 2010 and a hands-on
workshop in next generation sequencing at the University of Pittsburgh/ Pittsburgh Supercomputing
Center in 2013.
His research areas include pharmacogenomics, pharmacokinetics, pharmacometrics and kinetics of
drug action. From 1999 to 2004, Dr. Duconge headed the Pharmacokinetic Lab, Center for Biological
Evaluation and Research in Havana, performing over 34 research projects and receiving 4 research
grants. Since 2005 to date, he has completed various pharmacogenetic studies to determine
prevalence of multiple pharmacogenes in the Puerto Rican population and their clinical association to
medical outcomes. He also developed a novel PGt-guided algorithm to predict optimal warfarin doses
in Puerto Ricans and measures of admixture pattern in this minority population. Moreover, a
pharmacokinetic study of intermittent intravenous vitamin C infusions at high doses in prostate
cancer patients was conducted. Currently, he is working on the physiogenomic analysis of the
Caribbean Hispanics in order to infer their population structure and admixture pattern by using
physiogenomic and ancestry markers, and also conducting pharmacogenetic association studies and
implementing a DNA-guided algorithm for optimal warfarin management and dosing in Caribbean
Hispanics. He is the author of more than 50 scientific publications including reviews, book chapters
and research articles in peer-reviewed journals.
Other Positions
Title
Investigator (WOC)
Institution
VA Caribbean Healthcare System
Department Pharmacy
Division
Research
Title
Collaborator
Institution
Hartford Hospital
Department
Division
Genetics Research Center
Awards and Honors
1995
University of Havana, Cuba - Summa Cum Laude
1999
National Council of Scientific Degrees, Cuba - Best PhD Thesis in Pharmaceutical
Sciences
2002
Cuban Public Health Services - Annual National Prize of Health Sciences
2006 2009 School of Pharmacy, UPR-MSC - Teacher of the Year
2007
NIH - Grant#5P20RR01112, Clinical Research Center infrastructure initiative Pilot
Projects Award (RCRII)
2008
NICHD, NIH - Grant#5G11HDO46326, EARDA Program
2008 2011 UPR-MSC RCMI Program; NCRR, NIH - RCMI Mentorship Award
2011 2014 NHLBI, NIH - Grant#HL110393, PGt of Warfarin in Puerto Rican Patients using a
Physiogenomics Approach (SC2)
2013
American Society of Health-System Pharmacists (ASHP) - 2013 ASHP Foundation
Literature Award
2014 2018 NHLBI, NIH - Grant#HL123911, Genomic Approach to Warfarin Dose Prescription in
Admixed Caribbean Hispanics (SC1)
Proceedings of Meetings
1. Bermudez-Bosch LA, Rivera G, Cruz I, Felici M, Ramos A, Duconge J. . American Journal of
Hematology. A Proposal for an Individualized Pharmacogenetic-guided warfarin Dosage
Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy. 2014; 89(1):E1.
2. Karla Claudio-Campos K, Orengo-Mercado C, Berrios L, Pagan R, Renta J, Cadilla C, Duconge J.
. The FASEB Journal. CYP2C9*8 frequency distribution in Puerto Ricans: implications for
warfarin dosing. 2014; 28(1):1141.10.
3. Ramos AS, Alejandro Y, Vazquez J, Valentin I, Rivera G, Cruz I, Cadilla CL, Renta J, Duconge J. .
American Journal of Hematology. Pharmacogenetic-driven Warfarin Dosing Algorithm in
Puerto Ricans. 2014; 89(1):E4.
4. Lojo L, Duconge J, Santiago-Borrero PJ. Pediatric Blood & Cancer. Integrating Combinatorial
CYP2C9 and VKORC1 Genotypes into Clinical Warfarin Management in Puerto Rican Children
with Thrombosis: An Illustrative Cases Study. 2010; 54(6):811-P162.
Reviews/Chapters/Editorials
1. Duconge J. J Pharmacogenomics Pharmacoproteomics. Population Heterogeneity and
Genomic Admixture: Relevance for Global Pharmacogenetics. 2014; 5(5):e141.
2. Duconge J, Escalera O, Korchela M, Ruaño G. Clinical Implications of Genetic Admixture in
Hispanic Puerto Ricans: Impact on the Pharmacogenetics of CYP2C19 and PON1, D. Sanoudou
(ed.). In: Clinical Applications of Pharmacogenetics, Chapter 7,. 2012; 151-164.
3. Seip RL, Duconge J, Ruaño G. Genotype-Guided Statin Therapy. In: Pharmacogenomic Testing
in Current Clinical Practice: Implementation in the Clinical Laboratory. A.H.B. Wu and K.T.J.
Yeo (eds.). Molecular and Translational Medicine series. Chapter 10; Springer Science &
Business Media (Humana Press), LLC, doi: 10.1007/978-1-60761-283-4. 2011; 155-174.
Abstracts
1. Ramos AS, Alejandro-Cowan Y, Vazquez J, Valentin I, Rivera G, Renta J, Cruz I, Feliu JF, Cadilla
CL, Seip R, Ruaño G, Duconge J. J Thrombosis and Thrombolysis. Pharmacogenetic-driven
warfarin dosing algorithm in Puerto Rican patients. In: Warfarin Dosing Management/
Abstract J3. Special Issue: Proceedings of the 12th National Conference on Anticoagulant
Therapy. 2013; 3(35):417.
2. Valentin II, Rivera G, Nieves M, Vazquez J, Cruz I, Renta J, Feliu JF, Cadilla CL, Duconge J.
American Journal of Hematology. A Pharmacogenetic Safety Profile of Puerto Ricans on
Warfarin Therapy. A10. THSNA meeting proceedings. 2012; 87(Suppl. 1):S152.
Publications
1.
Céspedes-Garro C, Naranjo MG, Rodrigues-Soares F, LLerena A, Duconge J, PubMed
Montané-Jaime LK, Roblejo H, Fariñas H, Campos ML, Ramírez R, Serrano V,
Villagrán CI, Peñas-LLedó EM. Pharmacogenetic research activity in Central America
and the Caribbean: a systematic review. Pharmacogenomics. 2016 Oct;
17(15):1707-1724.
2.
Duconge J, Ruaño G. Admixture and ethno-specific alleles: missing links for global PubMed
pharmacogenomics. Pharmacogenomics. 2016 Sep; 17(14):1479-82.
3.
Duconge J, Ramos AS, Claudio-Campos K, Rivera-Miranda G, Bermúdez-Bosch L, PubMed
Renta JY, Cadilla CL, Cruz I, Feliu JF, Vergara C, Ruaño G. A Novel Admixture-Based
Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS
One. 2016; 11(1):e0145480.
4.
Claudio-Campos K, Orengo-Mercado C, Renta JY, Peguero M, García R, Hernández G, PubMed
Corey S, Cadilla CL, Duconge J. Pharmacogenetics of healthy volunteers in Puerto
Rico. Drug Metabol Personal Ther. 2015 Dec; 30(4):239-49.
5.
Duconge J, Ruaño G. Fixed-dose combination products and unintended drug PubMed
interactions: urgent need for pharmacogenetic evaluation. Pharmacogenomics.
2015; 16(15):1685-8.
6.
Duconge J, Cadilla CL, Seip RL, Ruaño G. Why admixture matters in genetically- PubMed
guided therapy: missed targets in the COAG and EU-PACT trials. P R Health Sci J.
2015 Sep; 34(3):175-7.
7.
Miranda-Massari JR, Gonzalez MJ, Fernando AS, Cidre C, Paz IM, Charvel J, Martínez
V, Duconge J, Aponte A, Ricart CM. Metabolic Correction as a tool to improve
diabetes type 2 management. Bol Asoc Med P R. 2015 Apr-Jun; 107(2):54-9.
8.
Miranda-Massari JR, González MJ, Rodriguez-Gomez JR, Duconge J, Allende-Vigo PubMed
MZ, Jiménez Ramirez FJ, Cintrón K, Ricart C, Zaragoza-Urdaz R, Berdiel MJ, Vázquez
A. [Metabolic correction: a biochemical option against diseases]. Bol Asoc Med P R.
2015 Apr-Jun; 107(2):60-6.
9.
González MJ, Miranda-Massari JR, Duconge J, Allende-Vigo MZ, Jiménez-Ramírez FJ, PubMed
Cintrón K, Rodríguez-Gómez JR, Rosario G, Ricart C, Santiago-Cornier JA, ZaragozaUrdaz R, Vázquez A, Hickey S, Jabbar-Berdiel M, Riordan N, Ichim T, Santiago O,
Alvarado G, Vora P. Metabolic correction: a functional biochemical mechanism
against disease--Part 1: concept and historical background. P R Health Sci J. 2015
Mar; 34(1):3-8.
PubMed
10. Miranda-Massari JR, González MJ, Duconge J, Allende-Vigo MZ, Jiménez-Ramírez FJ, PubMed
Hickey S, Vázquez A, Berdiel MJ, Cintrón K, Rodríguez-Gómez JR. Metabolic
correction: a functional biochemical mechanism against disease--Part 2:
mechanisms and benefits. P R Health Sci J. 2015 Mar; 34(1):9-13.
11. Humphries-Bickley T, Castillo-Pichardo L, Corujo-Carro F, Duconge J, Hernandez- PubMed
O'Farrill E, Vlaar C, Rodriguez-Orengo JF, Cubano L, Dharmawardhane S.
Pharmacokinetics of Rac inhibitor EHop-016 in mice by ultra-performance liquid
chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol
Biomed Life Sci. 2015 Feb 15; 981-982:19-26.
12. Claudio-Campos K, Duconge J, Cadilla CL, Ruaño G. Pharmacogenetics of drug- PubMed
metabolizing enzymes in US Hispanics. Drug Metabol Personal Ther. 2014 Nov 28.
13. Valentín II, Rivera G, Nieves-Plaza M, Cruz I, Renta JY, Cadilla CL, Feliu JF, Seip RL, PubMed
Ruaño G, Duconge J. Pharmacogenetic association study of warfarin safety
endpoints in Puerto Ricans. P R Health Sci J. 2014 Sep; 33(3):97-104.
14. Gonzalez MJ, Miranda-Massari JR, Berdiel MJ, Duconge J, Rodríguez-López JL, PubMed
Hunninghake R, Cobas-Rosario VJ. High Dose Intraveneous Vitamin C and
Chikungunya Fever: A Case Report. J Orthomol Med. 2014; 29(4):154-156.
15. Duconge J, Cadilla CL. CYP2D6's functional status associated with the length of PubMed
hospitalization stay in psychiatric patients: a twist in the tale or evidence that
matters? Biomark Med. 2013 Dec; 7(6):913-4.
16. Orengo-Mercado C, Nieves B, López L, Vallés-Ortiz N, Renta JY, Santiago-Borrero PJ, PubMed
Cadilla CL, Duconge J. Frequencies of Functional Polymorphisms in Three
Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican
Population. J Pharmacogenomics Pharmacoproteomics. 2013 Mar 27; 4(113).
17. Ramos AS, Seip RL, Rivera-Miranda G, Felici-Giovanini ME, Garcia-Berdecia R, PubMed
Alejandro-Cowan Y, Kocherla M, Cruz I, Feliu JF, Cadilla CL, Renta JY, Gorowski K,
Vergara C, Ruaño G, Duconge J. Development of a pharmacogenetic-guided
warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics. 2012 Dec;
13(16):1937-50.
18. Gonzalez MJ, Miranda Massari JR, Duconge J, Riordan NH, Ichim T, Quintero-Del-Rio PubMed
AI, Ortiz N. The bio-energetic theory of carcinogenesis. Med Hypotheses. 2012 Oct;
79(4):433-9.
19. Duconge J, Ruaño G. 'Generic to genetic' transition in cardiovascular and PubMed
neuropsychiatric drugs: opportunity for personalized medicine. Pharmacogenomics.
2012 Jul; 13(10):1097-100.
20. Valentin II, Vazquez J, Rivera-Miranda G, Seip RL, Velez M, Kocherla M, Bogaard K, PubMed
Cruz-Gonzalez I, Cadilla CL, Renta JY, Feliu JF, Ramos AS, Alejandro-Cowan Y,
Gorowski K, Ruaño G, Duconge J. Prediction of warfarin dose reductions in Puerto
Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann
Pharmacother. 2012 Feb; 46(2):208-18.
21. Gonzalez MJ, Miranda Massari JR, Duconge J, Riordan NH, Ichim T. Schedule PubMed
Dependence in Cancer Therapy: Intravenous Vitamin C and the Systemic Saturation
Hypothesis. J Orthomol Med. 2012 Jan 1; 27(1):9-12.
22. Miranda-Massari JR, Gonzalez MJ, Jimenez FJ, Allende-Vigo MZ, Duconge J. PubMed
Metabolic correction in the management of diabetic peripheral neuropathy:
improving clinical results beyond symptom control. Curr Clin Pharmacol. 2011 Nov;
6(4):260-73.
23. Rodríguez-Vélez R, Ortiz-Rivera OJ, Bower B, Gorowski K, Windemuth A, Villagra D, PubMed
Kocherla M, Seip RL, D'Agostino D, Vergara C, Ruaño G, Duconge J. Exposure to nontherapeutic INR in a high risk cardiovascular patient: potential hazard reduction
with genotype-guided warfarin (Coumadin) dosing. P R Health Sci J. 2010 Dec;
29(4):402-8.
24. González MJ, Miranda-Massari JR, Duconge J. Vitamin C and cancer: what can we PubMed
conclude--1,609 patients and 33 years later: comment on the article by Cabanillas. P
R Health Sci J. 2010 Dec; 29(4):410-1; author reply 411-2.
25. Duconge J, Ruaño G. The Emerging Role of Admixture in the Pharmacogenetics of PubMed
Puerto Rican Hispanics. J Pharmacogenomics Pharmacoproteomics. 2010 Oct 4;
1(101).
26. Villagra D, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Gorowski K, Bogaard K, PubMed
Renta JY, Cruz IA, Mirabal S, Seip RL, Ruaño G. CYP2C9 and VKORC1 genotypes in
Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.
Clin Chim Acta. 2010 Sep 6; 411(17-18):1306-11.
27. Seip RL, Duconge J, Ruaño G. Implementing genotype-guided antithrombotic PubMed
therapy. Future Cardiol. 2010 May; 6(3):409-24.
28. González MJ, Rosario-Pérez G, Guzmán AM, Miranda-Massari JR, Duconge J, PubMed
Lavergne J, Fernandez N, Ortiz N, Quintero A, Mikirova N, Riordan NH, Ricart CM.
Mitochondria, Energy and Cancer: The Relationship with Ascorbic Acid. J Orthomol
Med. 2010; 25(1):29-38.
29. Ruaño G, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Villagra D, Renta J, PubMed
Holford T, Santiago-Borrero PJ. Physiogenomic analysis of the Puerto Rican
population. Pharmacogenomics. 2009 Apr; 10(4):565-77.
30. Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, PubMed
Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Ruaño G. Prevalence of
combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for
warfarin management in Hispanics. Ethn Dis. 2009; 19(4):390-5.
31. Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, PubMed
Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Ruaño G. For the patient.
DNA makeup of Hispanic persons should be determined before warfarin
prescription. Ethn Dis. 2009; 19(4):479-80.
32. Duconge J, Cadilla CL, Renta JY, Silén-Rivera P, Piovanetti P, García-Berdecía R, PubMed
Castro-Rosario LM, Monzón S, Vélez L, Rosas G, Guerra JA, Santiago-Borrero PJ.
Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a
preliminary report. P R Health Sci J. 2008 Dec; 27(4):357-8.
33. Duconge J. Applying organ clearance concepts in a clinical setting. Am J Pharm Educ. PubMed
2008 Oct 15; 72(5):121.
34. LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip R, Duconge J, Ruaño PubMed
G. Integrating genomic based information into clinical warfarin (Coumadin)
management: an illustrative case report. Conn Med. 2008 Aug; 72(7):399-403.
35. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan NH. PubMed
Pharmacokinetics of vitamin C: insights into the oral and intravenous administration
of ascorbate. P R Health Sci J. 2008 Mar; 27(1):7-19.
36. Ducongé J, Merino N, Alvarez D, Beausoleil I, Fernández-Sánchez E, Rodríguez L, Burt PubMed
AD. Kinetics of monoclonal anti-epidermal growth factor receptor antibody (IOR
EGF/r3)-induced apoptosis in human carcinoma bearing nude mice. P R Health Sci J.
2008 Mar; 27(1):35-41.
37. Duconge J, Miranda-Massari JR, González MJ, Taylor PR, Riordan HD, Riordan NH, PubMed
Casciari JJ, Alliston K. Vitamin C pharmacokinetics after continuous infusion in a
patient with prostate cancer. Ann Pharmacother. 2007 Jun; 41(6):1082-3.
38. García-Santana MA, Duconge J, Sarmiento ME, Lanio-Ruíz ME, Becquer MA, PubMed
Izquierdo L, Acosta-Domínguez A. Biodistribution of liposome-entrapped human
gamma-globulin. Biopharm Drug Dispos. 2006 Sep; 27(6):275-83.
39. Duconge J. The case of biotech-derived product equivalence: much ado about PubMed
nothing? Curr Clin Pharmacol. 2006 May; 1(2):147-56.
40. Ducongé J, Rodríguez-Vera L, Valenzuela C, Alvarez D, Ramírez O, de la Luz- PubMed
Hernández KR, Rabeza-Legón EY, Casacó A, Fernández-Sánchez E. Pharmacokinetic
comparison of two recombinant human granulocyte colony-stimulating factor after
subcutaneous administration in rabbits. Eur J Pharm Biopharm. 2005 Oct; 61(3):1428.
41. Hernández-Bernal F, García-García I, González-Delgado CA, Valenzuela-Silva C, Soto- PubMed
Hernández R, Ducongé J, Cervantes-Llano M, Blanco-Garcés E, Rodríguez V, GarcíaVega Y, Bello-Rivero I, Olivera-Ruano L, López-Saura P. Bioequivalence of two
recombinant granulocyte colony-stimulating factor formulations in healthy male
volunteers. Biopharm Drug Dispos. 2005 May; 26(4):151-9.
42. Duconge J, Prats PA, Valenzuela C, Aguilera A, Rojas I, Becquer MA, Alvarez D, PubMed
Estrada L, Alfonso-Ortíz S, Hardy-Rando E, García-Pulpeiro O, Fernández-Sánchez E.
Topical disposition of two strengths of a 125I-rhEGF jelly in rat skin wounds.
Biopharm Drug Dispos. 2004 Jul; 25(5):193-201.
43. Ducongé J, Fernández-Sánchez E, Alvarez D. Interspecies scaling of the monoclonal PubMed
anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it
really suitable? Biopharm Drug Dispos. 2004 May; 25(4):177-86.
44. Duconge J, Castillo R, Crombet T, Alvarez D, Matheu J, Vecino G, Alonso K, Beausoleil PubMed
I, Valenzuela C, Becquer MA, Fernández-Sánchez E. Integrated pharmacokineticpharmacodynamic modeling and allometric scaling for optimizing the dosage
regimen of the monoclonal ior EGF/r3 antibody. Eur J Pharm Sci. 2004 Feb; 21(23):261-70.
45. Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva C, Hernandez-Bernal F, PubMed
Ferrero-Bibilonia J, Soto-Hernandez R, Cervantes-Llano M, Ducongé J, CorreaFernandez A, Olivera-Ruano L, Lopez-Saura P. Bioequivalence of two recombinant
interferon alpha-2b liquid formulations in healthy male volunteers. Drugs R D. 2004;
5(5):271-80.
46. Duconge J, Fernández-Sánchez E, Macías A, Castillo R, Garcia I, Beausoleil I, Amador PubMed
JF, Matheu J. Monoclonal anti-EGFreceptor antibody (ior-R3) pharmacokinetic study
in tumor bearing nude mice: role of the receptor-mediated endocytosis on drug
clearance. Eur J Drug Metab Pharmacokinet. 2002 Apr-Jun; 27(2):101-5.
47. Prats PA, Duconge J, Valenzuela C, Berlanga J, Edrosa CR, Fernández-Sánchez E. PubMed
Disposition and receptor-site binding of (125)I-EGF after topical administration to
skin wounds. Biopharm Drug Dispos. 2002 Mar; 23(2):67-76.
48. Fernandez-Sánchez E, Ducongé J, Castillo R, Garcia I, Beausoleil I, Macías A. PubMed
Monoclonal anti-epidermal growth factor receptor (ior EGF/r3) antibody
pharmacokinetic studies on nude mice I: a radio-receptor analysis applied to drug
serum quantification. J Pharm Pharmacol. 2002 Jan; 54(1):59-64.
49. Morales AA, Ducongé J, Alvarez-Ruiz D, Becquer-Viart ML, Núñez-Gandolff G, PubMed
Fernández E, Caballero-Torres I, Iznaga-Escobar N. Humanized versus murine antihuman epidermal growth factor receptor monoclonal antibodies for
immunoscintigraphic studies. Nucl Med Biol. 2000 Feb; 27(2):199-206.
50. Morales AA, Núñez-Gandolff G, Pérez NP, Véliz BC, Caballero-Torres I, Ducongé J, PubMed
Fernández E, Crespo FZ, Veloso A, Iznaga-Escobar N. Freeze-dried formulation for
direct 99mTc-labeling ior-egf/r3 MAb: additives, biodistribution, and stability. Nucl
Med Biol. 1999 Aug; 26(6):717-23.
51. Morales-Morales A, Ducongé J, Caballero-Torres I, Núñez-Gandolff G, Fernández E, PubMed
Iznaga-Escobar N. Biodistribution of 99mTc-labeled anti-human epidermal growth
factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model
of human lung adenocarcinoma. Nucl Med Biol. 1999 Apr; 26(3):275-9.
52. Iznaga Escobar N, Morales AM, Ducongé J, Torres IC, Fernández E, Gómez JA. PubMed
Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human
epidermal growth factor receptor humanized monoclonal antibody R3 in rats. Nucl
Med Biol. 1998 Jan; 25(1):17-23.
THANK YOU FOR USING THE RTRN RESEARCH COLLABORATION AND PROFESSIONAL
NETWORKING SERVICE.
RTRN Data Coordinating Center
Mississippi e-Center @ Jackson State University
1230 Raymond Road, Box 1800, Jackson, Mississippi 39204
Phone: 601-979-0332, Fax: 601-979-0338, e-mail: [email protected]